Empazin
Generic Name
empazin-10-mg-tablet
Manufacturer
Beximco Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| empazin 10 mg tablet | ৳ 15.00 | ৳ 150.00 |
Description
Overview of the medicine
Empazin is an oral medication used to treat type 2 diabetes mellitus, heart failure, and chronic kidney disease. It belongs to a class of drugs called SGLT2 inhibitors.
Uses & Indications
Dosage
Adults
Initial dose 10 mg once daily, taken in the morning with or without food. May be increased to 25 mg once daily if needed and tolerated for glycemic control.
Elderly
No specific dose adjustment needed based on age alone. Renal function should be assessed before initiation and periodically.
Renal_impairment
Not recommended to initiate if eGFR <30 mL/min/1.73m². Continue 10 mg if eGFR falls below 30 mL/min/1.73m² if patient is already on it for heart failure or CKD. Dose adjustment is not needed for mild to moderate renal impairment.
How to Take
Oral. Take once daily in the morning with or without food.
Mechanism of Action
Empazin inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. It also has cardiovascular and renal protective effects independently of its glycemic control.
Pharmacokinetics
Onset
Glycemic effects observed within hours; full therapeutic effects may take longer.
Excretion
Approximately half excreted via urine and half via feces.
Half life
Approximately 12.4 hours.
Absorption
Rapidly absorbed, peak plasma concentration (Cmax) reached within 1.5 hours.
Metabolism
Primarily metabolized by glucuronidation in the liver.
Side Effects
Contraindications
- •Hypersensitivity to empazin or any excipients.
- •Patients with severe renal impairment (eGFR <30 mL/min/1.73m²) for initiation of glycemic control.
- •Type 1 Diabetes Mellitus (due to risk of DKA).
- •Diabetic ketoacidosis (DKA).
Drug Interactions
Lithium
May decrease lithium levels due to increased urinary excretion.
Diuretics
Increased risk of dehydration and hypotension.
Insulin/Sulfonylureas
Increased risk of hypoglycemia (dose reduction of insulin/sulfonylureas may be needed).
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
Overdose may lead to symptoms of dehydration. Management involves symptomatic treatment and supportive measures. Dialysis is not expected to be effective in removing empazin.
Pregnancy & Lactation
Not recommended during pregnancy (Pregnancy Category C) or lactation. Consult your doctor for alternatives.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture.
Availability
Pharmacies, hospitals
Approval Status
Approved
Patent Status
Patent protected
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
